How do I buy shares of Pear Therapeutics?

Shares of PEAR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:PEAR

Pear Therapeutics (PEAR) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free PEAR Stock Alerts

Compare

Today's Range: N/A
50-Day Range: N/A
52-Week Range: N/A

Volume: N/A
Average Volume: 7.75 million shs
Market Capitalization: $4.17 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Competitors Financials Headlines Insider Trades Ownership SEC Filings Social Media

Get Pear Therapeutics alerts:

Ad Paradigm Press

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

About Pear Therapeutics Stock (NASDAQ:PEAR)

Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal, oncology, and cardiovascular. Pear Therapeutics, Inc. was incorporated in 2013 and is based in Boston, Massachusetts.

Ad Paradigm Press

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

Click here to find out that this 8,788% cryptocurrency is.

PEAR Stock News Headlines

April 18, 2024 | yahoo.com

Work on Highway 99 northbound lanes near Avenue 12 begins

April 9, 2024 | msn.com

Exclusive: AlleyCorp raises a $250 million fund, taking on external investors for the first time

April 20, 2024 | Paradigm Press (Ad)

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

April 5, 2024 | msn.com

FDA approves first prescription-only app for depression

April 1, 2024 | finance.yahoo.com

Acorda Therapeutics and Merz Announce Signing of "Stalking Horse" Asset Purchase Agreement

April 1, 2024 | wsj.com

Acorda Therapeutics Files for Bankruptcy Protection

March 28, 2024 | forbes.com

Virtual Clinic Pelago Is Reimagining Rehab With $58 Million In New Funding

March 19, 2024 | bizjournals.com

Girl's rare disease inspired new drug model. Now the drug trial has hit a pivotal point

April 20, 2024 | Paradigm Press (Ad)

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

March 15, 2024 | finance.yahoo.com

Better Therapeutics lays off staff, considers winding down business

March 14, 2024 | finance.yahoo.com

Bratu named marketing and development director for State Games

February 21, 2024 | finance.yahoo.com

Better Therapeutics wins breakthrough status for health app to treat liver disease

January 31, 2024 | finance.yahoo.com

Global Internet Addiction Disorder Market Size Is Expected To Hold a Significant Share By 2033 | CAGR of 11.45%

January 31, 2024 | finance.yahoo.com

Smart Pills Market Set to Soar Past USD 12.39 billion by 2030

January 31, 2024 | forbes.com

How Pharma Can Borrow A Page From Digital Health Investors’ Playbook

January 31, 2024 | axios.com

Cognito Therapeutics raises $35M for neuro device

January 26, 2024 | finance.yahoo.com

Healthcare bankruptcies reached five-year peak in 2023, report finds

January 11, 2024 | finance.yahoo.com

Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025

December 20, 2023 | finance.yahoo.com

Digital Therapeutics Global Market to Observe Stunning Growth at a CAGR of ~28% by 2028 | DelveInsight

November 11, 2023 | morningstar.com

Pear Therapeutics Inc Class A PEARQ

November 9, 2023 | finance.yahoo.com

Nox Health Appoints Frances Thorndike, Ph.D. to lead Medical & Scientific Affairs

October 27, 2023 | seekingalpha.com

PEARQ Pear Therapeutics, Inc.

October 24, 2023 | benzinga.com

Digital Therapeutics Market Is Projected to Gain $22.60 Billion By 2031, Growing at a 19.4% CAGR: Allied Market Research

October 18, 2023 | bizjournals.com

Deals of the Year: Somryst 'literally completes our portfolio,' Nox Health CEO says

October 10, 2023 | bizjournals.com

Biotech's 2023 ghosts haunt efforts to exorcise downturn

September 28, 2023 | benzinga.com

Migraine Pipeline, Clinical Trials, Emerging Therapies and FDA Approvals 2023 (Updated)

September 25, 2023 | finance.yahoo.com

Pear Therapeutics, Inc. (PEARQ)

See More Headlines

Receive PEAR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pear Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Health services
Sub-Industry: N/A
Current Symbol: NASDAQ:PEAR
CUSIP: N/A
CIK: 1835567
Web: peartherapeutics.com
Phone: 617-925-7848
Fax: N/A
Employees: 300
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.22)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-75,490,000.00
Net Margins: -594.70%
Pretax Margin: -594.70%
Return on Equity: -217.85%
Return on Assets: -95.20%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.48
Quick Ratio: 1.48

Sales & Book Value

Annual Sales: $12.69 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.22 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 142,739,000
Free Float: 98,918,000
Market Cap: $4.17 million
Optionable: Not Optionable
Beta: 0.45

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Corey M. McCann M.D. (Age 43)
Ph.D., Founder, Pres, CEO & Director
Comp: $702.45k
Mr. Christopher D. T. Guiffre J.D. (Age 55)
M.B.A., MBA, CFO, COO, Treasurer & Assistant Sec.
Comp: $564.37k
Ms. Julia M. Strandberg M.B.A. (Age 48)
Chief Commercial Officer
Comp: $582.43k
Mr. Ronan P. O'Brien J.D. (Age 50)
Chief Compliance Officer, Gen. Counsel & Sec.
Ms. Meara Murphy
Sr. Director of Corp. Communications
Dr. Yuri Maricich M.B.A. (Age 43)
M.D., Chief Medical Officer & Head of Devel.
Mr. Chris Valosky M.B.A.
VP of Sales
Ms. Katherine Jeffery M.Sc. (Age 56)
Chief People Officer
Ms. Erin K. Brenner (Age 50)
Chief Product Devel. Officer
Ms. Ellen E. Snow CPA (Age 50)
CGMA, VP & Corp. Controller

Key Competitors

View All Competitors

PEAR Stock Analysis - Frequently Asked Questions

How do I buy shares of Pear Therapeutics?: Shares of PEAR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PEAR) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Pear Therapeutics (PEAR) Stock Price, News & Analysis

About Pear Therapeutics Stock (NASDAQ:PEAR)

PEAR Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

PEAR Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info